NCT01538472 - Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions

Lymphoma

Interventions

DRUG

Y Zevalin

Starting dose: 0.4 mCi/kg by vein after Rituxan infusion on Day -14.

DRUG

In Zevalin

Imaging dose: 5 mCi by vein following Rituxan infusion on Day -21.

DRUG

Rituxan

"250 mg/m2 by vein on Day -21 and on Day -14.~1000 mg/m2 by vein on Days +1 and +8."

DRUG

BCNU

300 mg/m2 by vein on Day -6.

DRUG

VP -16

200 mg/m2 by vein every 12 hours on Days -5, -4, -3, and -2.

DRUG

Ara-C

200 mg/m2 by vein every 12 hours on Days -5, -4, -3,and -2.

DRUG

Melphalan

140 mg/m2 by vein on Day -1.

PROCEDURE

Stem Cell Infusion

Autologous stem cell infusion on Day 0.

DRUG

G-CSF

5 mg/kg by vein daily starting Day 0 till recovery of granulocytes of 4.0 x 109/L.

Trial Locations (1)

UT MD Anderson Cancer Center, Houston